Adicet Bio, Inc. (ACET)

1,7300 +0,0400 (+2,37%) Börsenschluss: 04:00PM EDT

Adicet Bio, Inc.

131 Dartmouth Street
3rd Floor
Boston, MA 02116
United States
650 503 9095
https://www.adicetbio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 143

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Chen Schor BA, CPA, M.B.A.	CEO, President & Director	871,97k	N/A	1972
Dr. Aya Jakobovits Ph.D.	Founder & Independent Director	45k	N/A	1955
Mr. Brian Nicholas Harvey	Chief Financial Officer	594,94k	N/A	1961
Dr. Donald Healey Ph.D.	Chief Technology Officer	606,34k	N/A	1962
Dr. Blake Aftab Ph.D.	Senior VP & Chief Scientific Officer	675,04k	N/A	1981
Ms. Amy Locke	Chief Human Resource Officer	N/A	N/A	N/A
Dr. Francesco Galimi M.D., Ph.D.	Chief Medical Officer & Senior VP	680,37k	N/A	1968
Dr. Nancy L. Boman M.D., Ph.D.	Senior VP & Chief Regulatory Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Corporate Governance

Adicet Bio, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 6, Vorstand: 9, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.